European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

MeSH terms

• Cardiology / organization & administration
• Cardiovascular Agents* / adverse effects
• Cardiovascular Agents* / therapeutic use
• Cardiovascular Diseases* / drug therapy
• Cardiovascular Diseases* / mortality
• Cardiovascular Diseases* / prevention & control
• Cholesterol / blood
• Consensus
• Enzyme Inhibitors* / adverse effects
• Enzyme Inhibitors* / therapeutic use
• Humans
• Hyperlipoproteinemia Type II* / drug therapy
• Hyperlipoproteinemia Type II* / mortality
• Hyperlipoproteinemia Type II* / prevention & control
• PCSK9 Inhibitors*
• Practice Guidelines as Topic
• Risk Factors